Browsing: Pharmaceuticals

After months of anticipation, the Food and Drug Administration gave tentative approval to Dr. Reddy’s Laboratories to make a generic version of a groundbreaking HIV prevention medicine, a key step in widening access for dozens of low- and middle-income countries.

What is Adam doing in Spain? How did doctors react to detailed data on Merck and Moderna’s mRNA cancer vaccine? And what are the next big advances in oncology?

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.

The Department of Health and Human Services released a policy that will temporarily allow compounding pharmacies to manufacture some peptide products, increasing access to the experimental wellness therapies embraced by many in the Make America Healthy Again movement

A House lawmaker asked the Government Accountability Office to review whether the TrumpRx platform has saved Americans any money.

The Food and Drug Administration published draft guidance on Tuesday that would streamline approvals of some individualized gene therapies, a win for rare disease advocates who have criticized the agency’s approach to these treatments

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.

Missouri Attorney General Catherine Hanaway (R) has warned Eli Lilly to discontinue its practice of requiring hospitals to provide claims data to receive discounted medicines under a federal program, a sign that more states are pushing back against such moves by drugmakers.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

In the past week, a GSK cancer drug picked up an approval for another tumor type, the company unveiled the first data from a global study of a promising next-generation chemotherapy, and a medicine that the firm has licensed got the limelight in a presidential session at a major oncology conference here